Clinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy

References

• Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13(2):1–12. doi: 10.1016/s0272-6386(89)80134-9.
   Web of Science ®Google Scholar
• Fan WJ, Ge YC, Zhou Y, et al. Fenofibrate in the treatment of patients with lipoprotein nephropathy. Chin J Nephrol Dial Transplant. 2016;25:25–29.
   Google Scholar
• Chen S, Liu ZH, Zheng JM, et al. Genomic analysis of apolipoprotein E gene in patients with lipoprotein glomerulopathy. Chin J Nephrol Dial Transplant. 2005;14:218–223.
   Google Scholar
• Chen TY, Li GS, Zou YR, et al. Clinical characteristics and apolipoprotein E gene mutation in patients with lipoprotein glomerulopathy. Pract J Clin Med. 2013;10:57–59.
   Google Scholar
• Wu HY, Yang Y, Hu ZX. The novel apolipoprotein E mutation ApoE chengdu (c.518T > C, p.L173P) in a Chinese patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2018;25(8):733–740. doi: 10.5551/jat.41996.
   PubMed Web of Science ®Google Scholar
• Hu ZX, Huang SM, Wu Y, et al. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. Kidney Int. 2014;85(2):416–424. doi: 10.1038/ki.2013.335.
   PubMed Web of Science ®Google Scholar
• Pan YL, Chen YQ, Zhang H, et al. Screening for apolipoprotein E gene mutations in 4 patients with lipoprotein glomerulopathy. Chin J Nephrol. 2006;22:449–453.
   Google Scholar
• Zou GM, Zhuo L, Tan M, et al. Clinicopathologic features of lipoprotein glomerulopathy: observation of 6 cases. Natl Med J China. 2018;98:2910–2913.
   Google Scholar
• Chen YQ, Zhang H, Zhu SL, et al. A3-amino acid deletion of apolipoprotein E found in 3 Chinese lipoprotein glomerulopathy patients. Zhonghua Yi Xue Za Zhi. 2003;83(9):774–777.
   PubMedGoogle Scholar
• Ku M, Tao C, Zhou AA, et al. A novel apolipoprotein E mutation (p.Arg150Cys) in a Chinese patient with lipoprotein glomerulopathy. Chin Med J (Engl). 2019;132(2):237–239. doi: 10.1097/CM9.0000000000000050.
   PubMed Web of Science ®Google Scholar
• Zhang B, Weng DS. Analysis of the relationship between the clinical manifestations and pathological characteristics of lipoprotein nephropathy. Chin J Integ Traditional Western Nephrol. 2005;6:463–465.
   Google Scholar
• Luo BX, Huang FX, Liu QC, et al. Apolipoprotein E guangzhou (arginine150 proline): a new variant in lipoprotein glomerulopathy. Chin J Nephrol. 2007;23:711–715.
   Google Scholar
• Ma S, Zhao ZZ, Wang XY, et al. Clinical features and pathological characteristics of lipoprotein glomerulopathy. J Med Forum. 2013;34:35–37.
   Google Scholar
• Chen J, Zhao XH, He HS, et al. Two cases of double filtration plasmapheresis treatment for familial hyperlipoproteinemia nephropathy. Pract J Med Pharm. 2012;10:930.
   Google Scholar
• Jia L, Zhang JJ, Shi PP, et al. One case report of lipoprotein glomerulopathy with literature review. J Clin Pediatr. 2016;2:120–124.
   Google Scholar
• Li Y, Chen J, Zou Y, et al. Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: a case report. Medicine (Baltimore). 2022;101(5):e28718. doi: 10.1097/MD.0000000000028718.
   PubMed Web of Science ®Google Scholar
• Wu H, Yang J, Liu YQ, et al. Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice. J Transl Med. 2021;19(1):97. doi: 10.1186/s12967-021-02765-x.
   PubMed Web of Science ®Google Scholar
• Han J, Pan Y, Chen Y, et al. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. Nephron Clin Pract. 2010;114(4):c260–267. doi: 10.1159/000276578.
   PubMedGoogle Scholar
• Saito T, Oikawa S, Sato H, et al. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron. 1999;83(3):193–201. doi: 10.1159/000045511.
   PubMed Web of Science ®Google Scholar
• Liu ZH. Lipoprotein nephropathy: new disease, new insights. Chin J Nephrol Dial Transplant. 2001;10:301–302.
   Google Scholar
• Saito T, Sato H, Oikawa S, et al. Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol. 1993;13(1):64–68. doi: 10.1159/000168591.
   PubMed Web of Science ®Google Scholar
• Bansal P, Dahate P, Raghuwanshi S, et al. Current updates on role of lipids in hematopoiesis. Infect Disord Drug Targets. 2018;18(3):192–198. doi: 10.2174/1871526518666180405155015.
   PubMedGoogle Scholar
• Hermetet F, Buffière A, Aznague A, et al. High-fat diet disturbs lipid raft/TGF-beta signaling-mediated maintenance of hematopoietic stem cells in mouse bone marrow. Nat Commun. 2019;10(1):523. doi: 10.1038/s41467-018-08228-0.
   PubMedGoogle Scholar
• Ping H, Liu ZH, Gong RJ, et al. Clinical manifestations and pathological characteristics of lipoprotein glomerulopathy. Chin J Nephrol. 2002;18:403–407.
   Google Scholar
• Yang JR, He YN, Lin LR, et al. One case of immunoadsorption therapy for severe lipoprotein nephropathy. Chin J Blood Purifi. 2006;5:816.
   Google Scholar
• Kinomura M, Sugiyama H, Saito T, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23(2):751–756. doi: 10.1093/ndt/gfm675.
   PubMed Web of Science ®Google Scholar
• Boumendjel R, Papari M, Gonzalez M. A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. Arch Pathol Lab Med. 2010;134(2):279–282. doi: 10.5858/134.2.279.
   PubMed Web of Science ®Google Scholar
• Li MS, Li Y, Liu Y, et al. An updated review and meta analysis of lipoprotein glomerulopathy. Front Med (Lausanne). 2022;9:905007. doi: 10.3389/fmed.2022.905007.
   PubMed Web of Science ®Google Scholar
• Ji SM, Liu M, Chen JS, et al. The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation. Clin Transplant. 2004;18(5):536–540. doi: 10.1111/j.1399-0012.2004.00206.x.
   PubMed Web of Science ®Google Scholar
• Toyota K, Hashimoto T, Ogino D, et al. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy. J Hum Genet. 2013;58(5):254–258. doi: 10.1038/jhg.2013.8.
   PubMed Web of Science ®Google Scholar
• Pêgas KL, Rohde R, Garcia CD, et al. Lipoprotein glomerulopathy: a case report of a rare disease in a Brazilian child. J Bras Nefrol. 2014;36(1):93–95. doi: 10.5935/0101-2800.20140015.
   PubMedGoogle Scholar
• Sam R, Wu H, Yue L, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis. 2006;47(3):539–548. doi: 10.1053/j.ajkd.2005.12.031.
   PubMed Web of Science ®Google Scholar
• Sipovskii VG, Klemina IK, Zverkov RV, et al. A case of diagnosing lipoprotein glomerulopathy in Russia. Arkh Patol. 2016;78(6):52–57. doi: 10.17116/patol201678652-57.
   PubMedGoogle Scholar
• Pasquariello A, Pasquariello G, Innocenti M, et al. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. J Nephrol. 2011;24(3):381–385. doi: 10.5301/JN.2011.7772.
   PubMed Web of Science ®Google Scholar
• Meyrier A, Dairou F, Callard P, et al. Lipoprotein glomerulopathy: first case in a white European. Nephrol Dial Transplant. 1995;10(4):546–549. doi: 10.1093/ndt/10.4.546.
   PubMed Web of Science ®Google Scholar
• Marinaki S, Kalaitzakis E, Kolovou K, et al. A case of lipoprotein glomerulopathy in a Greek caucasian male. Int Urol Nephrol. 2022;54(4):969–970. doi: 10.1007/s11255-021-02930-7.
   PubMed Web of Science ®Google Scholar
• Ting JA, McRae SA, Schwartz D, et al. Lipoprotein glomerulopathy, first case report from Canada. Int J Nephrol Renovasc Dis. 2022;15:207–214. doi: 10.2147/IJNRD.S364890.
   PubMed Web of Science ®Google Scholar
• Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47(2):199–211. doi: 10.1053/j.ajkd.2005.10.017.
   PubMed Web of Science ®Google Scholar
• Usui R, Takahashi M, Nitta K, et al. Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation. CEN Case Rep. 2016;5(2):148–153. doi: 10.1007/s13730-016-0214-5.
   PubMedGoogle Scholar
• Arai T, Yamashita S, Yamane M, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis. 2003;169(2):293–299. doi: 10.1016/s0021-9150(03)00194-1.
   PubMed Web of Science ®Google Scholar
• Zhan JF, Liu ZH, Li SJ, et al. Effect of immunoadsorption therapy in patients with lipoprotein glomerulopathy. Chin J Nephrol Dial Transplant. 2006;15:203–209.
   Google Scholar
• Xin Z, Liu ZH, Li SJ, et al. Successful treatment of patients with lipoprotein glomerulopathy by protein a immunoadsorption: a pilot study. Nephrol Dial Transplant. 2009;2:864–869.
   Google Scholar
• Academic committee of the people’s liberation army institute of nephrology. Whole blood lipoprotein adsorption therapy for lipoprotein nephropathy. Chin J Nephrol Dial Transplant. 2004;13:493–498.
   Google Scholar
• Li WC, Wang Y, Han ZW, et al. Apolipoprotein E mutation and double filtration plasmapheresis therapy on a new Chinese patient with lipoprotein glomerulopathy. Kidney Blood Press Res. 2014;39(4):330–339. doi: 10.1159/000355810.
   PubMed Web of Science ®Google Scholar
• Russi G, Furci L, Leonelli M, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (heparin-induced extracorporeal lipoprotein precipitation system): a case report. J Med Case Rep. 2009;3:9311.
   PubMedGoogle Scholar